Genmab — Juli 2020
-
"KdD significantly prolonged progression-free survival versus Kd in patients with relapsed or refractory multiple myeloma and was associated with a favourable benefit–risk profile".
-
God morgen.
-
Jeg fik taget et et stort ryk på hækken i går aftes. God motion med en almindelig gammeldags hæksaks.
-
Johnson & Johnson (JNJ) CEO Alex Gorsky on Q2 2020 Results - Earnings Call Transcript https://seekingalpha.com/article/4358910-johnson-johnson-jnj-ceo-alex-gorsky-on-q2-2020-results-earnings-call-transcript?part=single
-
Apropos GB 6,26: Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study - finally https://twitter.com/szusmani/status/1283914643048628225
-
Der er stor glæde i twitter-tråden.
-
Nyd også denne salgsoversigt: https://twitter.com/MidgardFinance/status/1283995307492220928/photo/1
-
-
Der er ikke megen grund til negative vinkler på Genmab-casen for øjeblikket.
-
https://finance.yahoo.com/news/sanofi-considers-u-biotech-targets-181537811.html Sanofi på M&A jagt med op til $50bn
-
Det er da også en slags penge.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind